JelliSee Ophthalmics, Inc.
The leader in accommodating IOL technology, and winner of the 2021 Winning Pitch Challenge @ ASCRS 2021
* The JelliSee IOL is an investigation device and is not approved for human use
* The JelliSee IOL is an investigation device and is not approved for human use
About UsJelliSee is an innovative medical device company that has developed a true accommodating and astigmatism-correcting monofocal intraocular lens (IOL) for patients with cataracts.
For over 20 years, an IOL that can provide clear vision across the full range of visual distances has been considered the Holy Grail of ophthalmology innovation and has been sought by ophthalmologists, patients, and industry. The JelliSee accommodating IOL is “the lens” that all have been seeking. At JelliSee, we envision a future where age related vision limitations are a thing of the past. With groundbreaking intraocular lens technology, our mission is to restore natural, seamless vision across all distances. |
|
Technology and Market Size
The JelliSee IOL achieves 7.0 diopters or more of accommodation with less than 0.2mm of diameter change. With a novel, patent-pending approach, JelliSee is a game changer in the treatment of cataracts.
The annual market potential for an effective accommodating IOL is in the billions of dollars. click here for more |